ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 803,20
1,47%
DAX
18 518,03
-0,44%
Brent Oil
83,485
-1,01%
Bitcoin
64 531,57
-0,49%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
03/03/201122h00Business WireAllos Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of FOLOTYN in Patients with Pre...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/201122h00Business WireAllos Therapeutics Reports Fourth Quarter and Full Year 2010 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/03/201123h10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/02/201115h00Business WireAllos Therapeutics to Report Fourth Quarter and Full Year 2010 Results on March 3, 2011NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
14/02/201122h40Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/02/201120h37Edgar (US Regulatory)Statement of Ownership (SC 13G)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/01/201100h31Business WireJournal of Clinical Oncology Publishes Results from Pivotal Phase 2 PROPEL Study of FOLOTYN® in Relapsed or Refractory Perip...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/01/201114h04Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/01/201114h00Business WireAllos Therapeutics Reports 2010 Financial Highlights and 2011 Key Business PrioritiesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
21/12/201014h00Business WireAllos Therapeutics’ Marketing Authorisation Application (MAA) for FOLOTYN® Accepted for Review by European Medicines Agenc...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/12/201014h00Business WireAllos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/12/201021h15Business WireNew Analysis from Phase 2b Study Reinforces Favorable Survival Data Observed with FOLOTYN® Relative to Erlotinib in Advanced...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/12/201015h00Business WireUpdated Results from FOLOTYN® Phase 1 Dose Finding Study Demonstrates Activity in Relapsed or Refractory Cutaneous T-Cell Ly...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/12/201015h00Business WireAllos Therapeutics Reports New Analyses of FOLOTYN® Data from PROPEL trial in Relapsed or Refractory Peripheral T-Cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/12/201015h00Business WireNew Analysis from FOLOTYN® PROPEL Trial Demonstrates Activity in Relapsed or Refractory Transformed Mycosis FungoidesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/12/201014h00Business WireAllos Therapeutics Announces FOLOTYN® Data to Be Presented as a Late Breaker at the 2010 Chicago Multidisciplinary Symposium...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/11/201014h00Business WireNew FOLOTYN® Data to Be Presented at the 2010 American Society of Hematology Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/11/201021h10Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/11/201021h00Business WireAllos Therapeutics Reports Third Quarter 2010 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/10/201022h00Business WireAllos Therapeutics to Report Third Quarter 2010 Financial Results on November 4, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/10/201016h06Dow Jones NewsAllos Granted Orphan Status In Europe For Lymphoma DrugNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/10/201015h00Business WireAllos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Hodgkin Lymphoma by the Eu...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/10/201014h19Dow Jones NewsAllos' Pralatrexate Outperforms Tarceva In Lung-Cancer StudyNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/10/201013h15Business WireAllos Therapeutics Announces Presentation of Favorable Survival Data from Randomized Phase 2b Study of FOLOTYN® in Patients ...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/10/201016h00GlobeNewswire Inc.Allos Therapeutics, Inc. (ALTH) to Ring The NASDAQ Stock Market Closing BellNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/09/201022h14Edgar (US Regulatory)Amended Current report filing (8-K/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/09/201023h40Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/09/201015h00Business WireAllos Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/09/201019h29Business WireAllos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO CongressNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/09/201023h50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

EU
VIV
Vivendi
EU
PX1
CAC 40
EU
LR
Legrand
EU
EN
Bouygues
EU
AF
Air FranceKLM
NYSE
JPM
JP Morgan Chase
EU
ORA
Orange
COIN
ETHUSD
Ethereum
EU
CAP
Capgemini
EU
RI
Pernod Ricard
EU
BNP
BNP Paribas
EU
CS
Axa
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés